On 12 Nov 2026 Humana closed at $443.68, +74.9% this year; market cap $54.05bn, P/E 43.4.
Health Care · Managed Health Care · NYSE · United States
Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell. The Insurance segment offers individual Medicare Advantage products, including health insurance benefits, including wellness programs, chronic care management, and care coordination; individual Medicare stand-alone prescription drug products (PDP); group Medicare advantage and Medicare stand-alone PDP; Medicare supplements; specialty and ancillary insurance comprising dental, vision, life and disability; and administrative services to arrange health care services for active-duty and retired military personnel and dependents, as well as pharmacy benefit managers. Its CenterWell segment operates full-service, value-based senior focused primary care centers under the Conviva Senior Primary Care and CenterWell Senior Primary Care brands; a management services organization; CenterWell Home Health, a home health provider; and OneHome, which manages post-acute patient needs, as well as provides pharmacy and hospice solutions. The company was formerly known as Extendicare Inc. and changed its name to Humana Inc. in April 1974. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.
| Market cap | $54.05bn |
| P/E (trailing) | 43.4 |
| EPS (TTM) | $10.22 |
| Beta | 0.64 |
| Dividend | $3.54 |
| Dividend yield | 0.80% |
| Ex-dividend date | 24 Dec 2026 |
| Latest report | 6 Nov 2026 |
| Next earnings | 5 Feb 2027 |
| YTD | +74.9% |
| 1Y | +86.9% |
| 3Y | -2.5% |
| 5Y | +0.9% |
| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $129.66bn | $1.19bn | $375.00m |
| 2024 | $117.81bn | $1.21bn | $2.39bn |
| 2023 | $106.44bn | $2.49bn | $2.98bn |
| 2022 | $92.92bn | $2.81bn | $3.47bn |
| 2021 | $83.65bn | $2.93bn | $946.00m |
We publish no single base value for Humana. Our valuation methods put it between $198.78 and $453.12 a share. The valuation code's reason: no point fair value: the two anchors behind it compound the same growth rate and differ only in how they end — a perpetuity at the terminal rate against a multiple on the final year — so the midpoint between them measures terminal treatment rather than what the business is worth. The published range is the same reading with the false precision removed: read it as the span the method supports, and treat neither edge as a point estimate. See every method
Call and put prices: our price for each next to the market's.
Open in the dashboard · Run a full Desk Run
Data as of 12 Nov 2026. Not investment advice.